mRNA-based therapeutics: looking beyond COVID-19 vaccines

被引：88

作者：

Parhiz, Hamideh ^{[1
]}

Atochina-Vasserman, Elena N. ^{[1
]}

Weissman, Drew ^{[1
]}

机构：

[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA

来源：

LANCET | 2024年 / 403卷 / 10432期

关键词：

EBOLA-VIRUS CHALLENGE; T-CELL RESPONSES; ZIKA VIRUS; POSTEXPOSURE PROTECTION; RABIES VACCINE; IN-VIVO; TRANSMISSION; DELIVERY; PROTEIN; IMMUNOGENICITY;

D O I：

10.1016/S0140-6736(23)02444-3

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Recent advances in mRNA technology and its delivery have enabled mRNA-based therapeutics to enter a new era in medicine. The rapid, potent, and transient nature of mRNA-encoded proteins, without the need to enter the nucleus or the risk of genomic integration, makes them desirable tools for treatment of a range of diseases, from infectious diseases to cancer and monogenic disorders. The rapid pace and ease of mass-scale manufacturability of mRNAbased therapeutics supported the global response to the COVID-19 pandemic. Nonetheless, challenges remain with regards to mRNA stability, duration of expression, delivery efficiency, and targetability, to broaden the applicability of mRNA therapeutics beyond COVID-19 vaccines. By learning from the rapidly expanding preclinical and clinical studies, we can optimise the mRNA platform to meet the clinical needs of each disease. Here, we will summarise the recent advances in mRNA technology; its use in vaccines, immunotherapeutics, protein replacement therapy, and genomic editing; and its delivery to desired specific cell types and organs for development of a new generation of targeted mRNA-based therapeutics.

引用

页码：1192 / 1204

页数：13

共 148 条

[1] mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials [J].

A Feldman, Robert ;

Fuhr, Rainard ;

Smolenov, Igor ;

Ribeiro, Amilcar ;

Panther, Lori ;

Watson, Mike ;

Senn, Joseph J. ;

Smith, Mike ;

Almarsson, Orn ;

Pujar, Hari S. ;

Laska, Michael E. ;

Thompson, James ;

Zaks, Tal ;

Ciaramella, Giuseppe .

VACCINE, 2019, 37 (25) :3326-3334

[2] Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms [J].

Akinc, Akin ;

Querbes, William ;

De, Soma ;

Qin, June ;

Frank-Kamenetsky, Maria ;

Jayaprakash, K. Narayanannair ;

Jayaraman, Muthusamy ;

Rajeev, Kallanthottathil G. ;

Cantley, William L. ;

Dorkin, J. Robert ;

Butler, James S. ;

Qin, LiuLiang ;

Racie, Timothy ;

Sprague, Andrew ;

Fava, Eugenio ;

Zeigerer, Anja ;

Hope, Michael J. ;

Zerial, Marino ;

Sah, Dinah W. Y. ;

Fitzgerald, Kevin ;

Tracy, Mark A. ;

Manoharan, Muthiah ;

Koteliansky, Victor ;

de Fougerolles, Antonin ;

Maier, Martin A. .

MOLECULAR THERAPY, 2010, 18 (07) :1357-1364

[3] Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses [J].

Alameh, Mohamad-Gabriel ;

Tombacz, Istvan ;

Bettini, Emily ;

Lederer, Katlyn ;

Sittplangkoon, Chutamath ;

Wilmore, Joel R. ;

Gaudette, Brian T. ;

Soliman, Ousamah Y. ;

Pine, Matthew ;

Hicks, Philip ;

Manzoni, Tomaz B. ;

Knox, James J. ;

Johnson, John L. ;

Laczko, Dorottya ;

Muramatsu, Hiromi ;

Davis, Benjamin ;

Meng, Wenzhao ;

Rosenfeld, Aaron M. ;

Strohmeier, Shirin ;

Lin, Paulo J. C. ;

Mui, Barbara L. ;

Tam, Ying K. ;

Kariko, Katalin ;

Jacquet, Alain ;

Krammer, Florian ;

Bates, Paul ;

Cancro, Michael P. ;

Weissman, Drew ;

Prak, Eline T. Luning ;

Allman, David ;

Locci, Michela ;

Pardi, Norbert .

IMMUNITY, 2021, 54 (12) :2877-+

[4] Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial [J].

Alberer, Martin ;

Gnad-Vogt, Ulrike ;

Hong, Henoch Sangjoon ;

Mehr, Keyvan Tadjalli ;

Backert, Linus ;

Finak, Greg ;

Gottardo, Raphael ;

Bica, Mihai Alexandru ;

Garofano, Aurelio ;

Koch, Sven Dominik ;

Fotin-Mleczek, Mariola ;

Hoerr, Ingmar ;

Clemens, Ralf ;

von Sonnenburg, Frank .

LANCET, 2017, 390 (10101) :1511-1520

[5] Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial [J].

Aldrich, Cassandra ;

Leroux-Roels, Isabel ;

Huang, Katell Bidet ;

Bica, Mihai Alexandru ;

Loeliger, Edde ;

Schoenborn-Kellenberger, Oliver ;

Walz, Lisa ;

Leroux-Roels, Geert ;

von Sonnenburg, Frank ;

Oostvogels, Lidia .

VACCINE, 2021, 39 (08) :1310-1318

[6] Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia (MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mut) deficiency [J].

Almasi, Timea ;

Guey, Lin T. ;

Lukacs, Christine ;

Csetneki, Kata ;

Voko, Zoltan ;

Zelei, Tamas .

ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (1)

[7] Cancer therapy and vaccination [J].

Aly, Hamdy A. A. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2012, 382 (1-2) :1-23

[8] Review the safety of Covid-19 mRNA vaccines: a review [J].

Anand, Pratibha ;

Stahel, Vincent P. .

PATIENT SAFETY IN SURGERY, 2021, 15 (01)

[9] A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes [J].

Arevalo, Claudia P. ;

Bolton, Marcus J. ;

Le Sage, Valerie ;

Ye, Naiqing ;

Furey, Colleen ;

Muramatsu, Hiromi ;

Alameh, Mohamad-Gabriel ;

Pardi, Norbert ;

Drapeau, Elizabeth M. ;

Parkhouse, Kaela ;

Garretson, Tyler ;

Morris, Jeffrey S. ;

Moncla, Louise H. ;

Tam, Ying K. ;

Fan, Steven H. Y. ;

Lakdawala, Seema S. ;

Weissman, Drew ;

Hensley, Scott E. .

SCIENCE, 2022, 378 (6622) :899-904

[10] A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus [J].

August, Allison ;

Attarwala, Husain Z. ;

Himansu, Sunny ;

Kalidindi, Shiva ;

Lu, Sophia ;

Pajon, Rolando ;

Han, Shu ;

Lecerf, Jean-Michel ;

Tomassini, Joanne E. ;

Hard, Marjie ;

Ptaszek, Leon M. ;

Crowe, James E. ;

Zaks, Tal .

NATURE MEDICINE, 2021, 27 (12) :2224-+

← 1 2 3 4 5 6 7 8 9 10 →